Vicore Pharma Holding AB (DE:6Y4)
FRANKFURT:6Y4
6Y4 Stock Chart & Stats
€0.92
€0.08(9.48%)
At close: 4:00 PM EST
€0.92
€0.08(9.48%)
Day’s Range― - ―
52-Week Range€0.52 - €1.18
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€261.84M
Enterprise Value€1.84B
Total Cash (Recent Filing)€1.17B
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.41
Next Earnings
May 06, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding281,525,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.47
Price to Sales (P/S)710.16
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.51Price Target Upside282.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€646.43K
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthNear-zero reported debt and an expanded equity base provide durable financial flexibility. This reduces bankruptcy risk and gives management time to advance clinical programs without immediate debt servicing pressure, supporting long-term R&D funding optionality.
Focused R&D Platform (AT2R)A clear scientific focus on the AT2R platform and a lead candidate (C21) for IPF creates a repeatable, technology-driven development pathway. Platform specialization can generate multiple indications or follow-on assets, increasing long-term upside if clinical proof-of-concept is achieved.
Clinical-stage, Asset-light ModelAs a clinical-stage biotech, the company is asset-light relative to commercial peers, concentrating spend on R&D rather than manufacturing. This lower capital intensity can preserve cash and enable partnerships or licensing to scale later, benefiting long-term program economics.
Bears Say
Persistent Cash BurnConsistent and worsening negative operating cash flow forces reliance on external financing or equity raises. Over months to years this dilutes shareholders, constrains strategic choices, and raises execution risk for multi-phase clinical programs absent material non-dilutive funding or milestone revenues.
Revenue Volatility And DeclineA sharp revenue decline and high volatility undermine predictability of operating resources. For a clinical-stage firm, irregular revenue (grants, collaborations) increases funding uncertainty and complicates multi-year planning for trials, slowing sustainable growth prospects.
Large Operating Losses & Negative ROEDeep operating and net losses driving negative ROE indicate the company is not generating shareholder returns and will likely require continued capital raises. Structurally, persistent negative profitability increases dilution risk and means investors depend on binary clinical outcomes for value creation.
Vicore Pharma Holding AB News
6Y4 FAQ
What was Vicore Pharma Holding AB’s price range in the past 12 months?
Vicore Pharma Holding AB lowest stock price was €0.52 and its highest was €1.18 in the past 12 months.
What is Vicore Pharma Holding AB’s market cap?
Vicore Pharma Holding AB’s market cap is €261.84M.
When is Vicore Pharma Holding AB’s upcoming earnings report date?
Vicore Pharma Holding AB’s upcoming earnings report date is May 06, 2026 which is in 40 days.
How were Vicore Pharma Holding AB’s earnings last quarter?
Vicore Pharma Holding AB released its earnings results on Feb 27, 2026. The company reported -€0.05 earnings per share for the quarter, missing the consensus estimate of -€0.042 by -€0.008.
Is Vicore Pharma Holding AB overvalued?
According to Wall Street analysts Vicore Pharma Holding AB’s price is currently Undervalued.
Does Vicore Pharma Holding AB pay dividends?
Vicore Pharma Holding AB does not currently pay dividends.
What is Vicore Pharma Holding AB’s EPS estimate?
Vicore Pharma Holding AB’s EPS estimate is -0.04.
How many shares outstanding does Vicore Pharma Holding AB have?
Vicore Pharma Holding AB has 281,525,600 shares outstanding.
What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?
Vicore Pharma Holding AB reported an EPS of -€0.05 in its last earnings report, missing expectations of -€0.042. Following the earnings report the stock price went down -0.862%.
Which hedge fund is a major shareholder of Vicore Pharma Holding AB?
Currently, no hedge funds are holding shares in DE:6Y4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vicore Pharma Holding AB
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.
6Y4 Stock 12 Month Forecast
Average Price Target
€3.51
▲(282.02% Upside)
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---